US Price Negotiation Process: Is Case-By-Case Politically Sustainable?
Executive Summary
Republican Congressional letter asking HHS nuts-and-bolts questions about the newly enacted drug price ‘negotiation’ law points to a much more fundamental issue: can a bureaucratic agency make the program work in a manner that appears credible and free of undue political interference?
You may also be interested in...
Xtandi Still Faces Likely US Price Cut Even As It Avoids ‘March In’ Proceeding
The Biden administration decision not to pursue ‘march in’ proceedings for Pfizer/Astellas’ Xtandi sounds like good news. The reality is that the prostate cancer therapy is likely to face a more certain federal pricing intervention in the first year of the new Medicare ‘negotiation’ process.
US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin
The former Secretary of the US Department of Veterans Affairs, David Shulkin, discusses in an interview the US Inflation Reduction Act, telehealth, interoperability of healthcare data, and Mark Cuban’s pharma venture.
US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin
The former Secretary of the US Department of Veterans Affairs, David Shulkin, discusses in an interview with Scrip the US Inflation Reduction Act, telehealth, interoperability of healthcare data, and Mark Cuban’s pharma venture.